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1. Introduction 
Cycloheximide inhibits protein synthesis in a vari- 
ety of mammalian cells, including hepatocytes, L- 
cells, and reticulocytes [l] . The drug prevents the 
transfer of amino acids from aminoacyl-tRNA to the 
growing polypeptide chain [2] and evidence has been 
obtained showing that cycloheximide inhibits both 
peptide initiation and extension by an effect on the 
donor site on ribosomes [3]. After the administration 
of cycloheximide the formation of ribosomes and the 
synthesis of nuclear 45 S RNA in rat liver are also de- 
creased as a result of the reduced protein synthesis 
[4]. The mechanism of cycloheximide action is in- 
fluenced by adrenal secretion [S] ; in adrenalecto- 
mized rats no inhibition of amino acid incorporation 
into liver proteins has been observed [6]. 
Besides inhibiting protein synthesis cycloheximide 
increases tyrosine aminotransferase activity [7, 81. It 
has been concluded that degradation as well as syn- 
thesis of the enzyme must be blocked in the cyclo- 
heximide-treated animals [9]. In the present report 
evidence is presented showing that another liver en- 
zyme, uridine kinase, is influenced by the administra- 
tion of cycloheximide and related glutarimide anti- 
biotics. 
2. Methods 
The tested compounds were injected intraperitone- 
ally to groups of 4-10 male rats (170-180 g), kept 
under standard conditions. At different time intervals 
thereafter the animals were killed by cervical disloca- 
North-Holland Publishing Company ~ Amsterdam 
tion and excised livers were homogenized in a glass 
homogenizer with a Teflon pestle with 3 vol of ice- 
cold 0.25 M Tris-HCl buffer, pH 7.5, containing 25 
mM KC1 and 5 mM Mg”-ions. Homogenates were 
centrifuged (10,000 rpm, 20 min, 2”) and the defat- 
ted supernatant fractions were used immediately for 
the estimation of enzyme activity. 
Uridine kinase was assayed with 6-azauridine-2, 4- 
14C (44 pCi/pmole) as a substrate [lo] during a 10 
min incubation period at 37” in 0.05 M Tris-HCl buf- 
fer, pH 7.5, with 12 mM adenosine 5’-triphosphate 
(Calbiochem) and 6 mM Mg*+ ions in a total volume 
of 0.3 ml in the presence of 0.1 ml of cell-free liver 
extract corresponding to 25 mg of liver wet weight. 
Analysis of the reaction mixture was effected chroma- 
tographically on a Whatman No. 1 paper in the solvent 
system composed of 1 -butanol-acetic acid-water 
(10: 1:3). The radioactive zones were cut out with 
respect to standards and their radioactivity was as- 
sayed with a Packard liquid scintillation spectro- 
meter in 10 ml of scintillation fluid. The activity of 
uridine kinase was expressed as pmoles of phosphoryl- 
ated 6-azauridine per 1 g of liver during 1 hr of in- 
cubation. 
3. Results 
During our studies on liver regeneration we found 
that the activity of uridine kinase can be increased 
several times by the administration of 5-azacytidine 
[l 1,121. As obvious from the data presented in 
table 1, a similar increase can be observed also after 
the administration of pactamycin, cycloheximide, 
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Table 1 
Effect of various antibiotics on liver uridine kinase activity. 
June 1972 
Administered compound Dose level Uridine kinase 
(mglkg) (pmoles/gm/hr 2 S.E.) (%) 
Control 0 0.98 * 0.11 (100) 
Actinomycin D (Merck) 1 0.88 + 0.11 ( 90) 
Mitomycin C (Kyowa) 5 0.92 + 0.14 ( 94) 
Vancomycin (Lilly) 50 1.03 + 0.09 (105) 
Streptomycin (Jenapharm) 50 0.97 * 0.07 ( 99) 
Fusidic acid (Lbvens Kern. Fabrik) 2.5 1.01 * 0.08 (103 
Streptimidon (Dr. Z. Vant!k) 2.5 1.19 t 0.14 (121) 
Gougerotin (Calbiochem) 2.5 1.38 f 0.19 (141) 
Cycloheximide (Calbiochem) 2.5 2.00 + 0.20 (204) 
Streptovitacin A (Dr. Z. Van&k) 0.2 2.17 * 0.12 (222) 
Pactamycin (Dr. W. Kersten) 2.5 2.30 f 0.32 (235) 
The compounds were administered i.p. to groups of 5-8 male rats (170-180 g) 24 hr before killing. The incubation mixture 
for the determination of uridine kinase activity in cell-free liver extracts is described in Methods. 
and related glutarimide antibiotics. The action of 
pactamycin and especially of streptovitacin A (4-hy- 
droxycycloheximide) is more pronounced than the 
effect of cycloheximide. 
The time course of the enhancement of uridine 
kinase activity after the administration of cyclohexi- 
mide and streptovitacin A indicates a 6-8 hr lag-phase 
preceding the actual increase of enzyme activity (fig. 1). 
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Fig. 1. Uridine kinase activity in the liver of rats treated with 
cycloheximide (1.5 mg per kg) and streptovitacin A (0.3 mg 
per kg). The compounds were administered i.p. to groups of 
4-6 male rats (175- 180 g); at different time intervals, there- 
after the animals were killed and the activity of uridine kinase 
in cell-free liver extracts was assayed as described in Methods. 
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Starting 28-30 hr after the administration of the 
drugs, there is no further increase of the enzyme ac- 
tivity, and approx. 48-54 hr after the d&g adminis- 
tration the activity decreases to the level present in 
the control liver. The increase of uridine kinase in 
relation to the applied dose level of both compounds 
is shown in fig. 2. The administration of streptovitacin 
A brings about a rapid increase of uridine kinase ac- 
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Fig. 2. The increase of liver uridine kinase activity in relation 
to dose level of administered glutarimide antibiotics. The com- 
pounds were administered i.p, to groups of 4-6 male rats 
(170-180 g) 24 hr before killing. The activity of uridine 
kinase was assayed as described in Methods. 
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Table 2 
Stability of cycloheximide-mediated increase of liver uridine kinase. 
Administered compounds Dose level Uridine kinase Increase 
( mg/kg) @moles/gm/hr + SE.) (%) 
Control 
Cycloheximide 
5-Azacytidine (5-A&R) 
Cycloheximide + 5-AzCR 
Puromycin aminonucleoside 
Cycloheximide + Puromycin 
aminonucleoside 
0 
2 
10 
2+ 10 
90 
2 + 90 
1.06 f 0.13 100 
1.94 f 0.21 183 
1.76 * 0.17 166 
1.97 + 0.16 185 
0.78 + 0.12 74 
1.56 * 0.22 147 
The compounds were administered simultaneously via the intraperitoneal route to groups of 5- 10 male rats (175 g) 24 hr before 
killing. The determination of uridine kinase activity is described in Methods. 
tivity which reaches a maximum at the dose level of 
0.3 mg of the drug per kg. Higher doses of the anti- 
biotic are toxic [ 131 ; this is obviously related to the 
irreversible inhibition of protein synthesis after the 
application of the drug [ 141. The administration of 
increasing doses of cyloheximide results in the enhance- 
ment of uridine kinase with a maximum at the dose 
level 0.8-4.0 mg per kg. 
The data given in table 2 show that the increase of 
uridine kinase represents a relatively stable process. 
SAzacytidine resulting in a similar increase of uridine 
kinase [12] , does not cause any additional increase of 
the enzyme activity when administered in combination 
with cycloheximide. Simultaneous application of cyclo- 
heximide and puromycin aminonucleoside leads merely 
to a negligible decrease of the activity of the enzyme. 
4. Discussion 
We followed the activity of liver uridine kinase after 
the administration of antibiotics which interfere with 
different metabolic processes in the cell (table 1). Ac- 
tinomycin D [ 151 and mitomycin C [ 161 were em- 
ployed as inhibitors acting at the DNA level. As inhibi- 
tors of protein synthesis affecting the larger subunit of 
prokaryotic and eukaryotic ribosomes gougerotin-an 
inhibitor of peptidyl transferase [17]-and fusidic acid, 
inhibiting the translocation [ 181 were used. The data 
given in table 1 demonstrated that only glutarimide 
antibiotics and pactamycin cause an increase of liver 
uridine kinase. The drugs inhibit protein synthesis in 
eukaryotic systems only affecting the larger ribosomal 
subunit; pactamycin acts on the smaller one [17]. 
The increase of uridine kinase activity, observed 
after the administration of cycloheximide, reminds 
the finding of increased tyrosine aminotransferase 
activity [7-91, in spite of the fact that uridine kinase 
is not an inducible enzyme. The extensive application 
of cycloheximide in the studies on enzyme induction 
in various systems points to the differential sensitivity 
of different enzymes to cycloheximide (see e.g. [ 191). 
It appears that, in accordance to the results of Kenney 
[93 , cycloheximide interferes similarly to Sazacyti- 
dine [20] not only with the synthesis of enzymes but 
also with their degradation. The results obtained in 
studies on uridine kinase enhancement after the ad- 
ministration of Sazacytidine provide evidence of a rela- 
tively long half-life of template RNA of uridine kinase 
in the liver [21]. This finding together with the low 
inhibitory effect of puromycin aminonucleoside on 
uridine kinase activity (table 2) is not in contrast to 
the assumed inhibition of uridine kinase degradation 
following cycloheximide which would lead to an in- 
crease of its activity. 
The possible effect of the adrenal system and of 
the increased glucagon secretion on the increased ac- 
tivity of uridine kinase in the liver of animals treated 
with glutarimide antibiotics is under investigation. 
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